| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 102 | 2023 | 839 | 23.350 |
Why?
|
| Immunosuppressive Agents | 60 | 2022 | 514 | 12.070 |
Why?
|
| Graft Rejection | 60 | 2022 | 458 | 10.600 |
Why?
|
| Graft Survival | 51 | 2022 | 465 | 7.810 |
Why?
|
| Tacrolimus | 21 | 2023 | 127 | 7.370 |
Why?
|
| Transplant Recipients | 19 | 2021 | 109 | 7.300 |
Why?
|
| Kidney Failure, Chronic | 17 | 2023 | 365 | 4.930 |
Why?
|
| Healthcare Disparities | 13 | 2023 | 378 | 4.090 |
Why?
|
| Organ Transplantation | 12 | 2022 | 110 | 3.730 |
Why?
|
| Medication Adherence | 12 | 2021 | 335 | 3.220 |
Why?
|
| Drug Monitoring | 9 | 2021 | 107 | 3.060 |
Why?
|
| Retrospective Studies | 90 | 2022 | 7277 | 3.040 |
Why?
|
| Pharmacists | 14 | 2021 | 125 | 2.920 |
Why?
|
| Liver Transplantation | 18 | 2021 | 400 | 2.910 |
Why?
|
| Middle Aged | 113 | 2022 | 21147 | 2.800 |
Why?
|
| Longitudinal Studies | 33 | 2022 | 1054 | 2.630 |
Why?
|
| Adult | 106 | 2023 | 21403 | 2.580 |
Why?
|
| Male | 132 | 2022 | 37321 | 2.440 |
Why?
|
| Postoperative Complications | 17 | 2020 | 1615 | 2.390 |
Why?
|
| Female | 131 | 2022 | 38074 | 2.350 |
Why?
|
| Humans | 170 | 2023 | 68618 | 2.200 |
Why?
|
| Patient Readmission | 13 | 2018 | 267 | 2.180 |
Why?
|
| Aged | 70 | 2022 | 14862 | 2.060 |
Why?
|
| Telemedicine | 9 | 2021 | 700 | 2.020 |
Why?
|
| Risk Factors | 43 | 2021 | 5731 | 1.920 |
Why?
|
| Renal Insufficiency | 6 | 2020 | 121 | 1.860 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2017 | 148 | 1.830 |
Why?
|
| Delayed Graft Function | 8 | 2022 | 39 | 1.680 |
Why?
|
| Tissue and Organ Procurement | 5 | 2022 | 164 | 1.680 |
Why?
|
| United States | 39 | 2022 | 7367 | 1.670 |
Why?
|
| Pharmacy Service, Hospital | 6 | 2021 | 52 | 1.600 |
Why?
|
| Treatment Outcome | 48 | 2022 | 7029 | 1.600 |
Why?
|
| Living Donors | 6 | 2018 | 160 | 1.600 |
Why?
|
| Veterans | 8 | 2021 | 904 | 1.550 |
Why?
|
| Medication Errors | 8 | 2021 | 116 | 1.540 |
Why?
|
| Continuity of Patient Care | 4 | 2017 | 170 | 1.500 |
Why?
|
| Health Status Disparities | 7 | 2020 | 326 | 1.350 |
Why?
|
| Professional Role | 8 | 2021 | 80 | 1.350 |
Why?
|
| Cohort Studies | 23 | 2021 | 2358 | 1.310 |
Why?
|
| Health Policy | 3 | 2021 | 221 | 1.300 |
Why?
|
| Mobile Applications | 4 | 2021 | 138 | 1.290 |
Why?
|
| Patient Selection | 5 | 2021 | 592 | 1.290 |
Why?
|
| Drug Prescriptions | 3 | 2019 | 135 | 1.250 |
Why?
|
| Mycophenolic Acid | 8 | 2018 | 62 | 1.210 |
Why?
|
| Induction Chemotherapy | 3 | 2017 | 39 | 1.180 |
Why?
|
| Glomerular Filtration Rate | 9 | 2020 | 274 | 1.180 |
Why?
|
| Pancreas Transplantation | 10 | 2021 | 71 | 1.180 |
Why?
|
| Follow-Up Studies | 23 | 2019 | 3259 | 1.130 |
Why?
|
| Time Factors | 24 | 2020 | 4655 | 1.110 |
Why?
|
| Ambulatory Care | 3 | 2018 | 340 | 1.100 |
Why?
|
| Prospective Studies | 18 | 2023 | 3705 | 1.050 |
Why?
|
| Cytomegalovirus Infections | 5 | 2017 | 69 | 1.020 |
Why?
|
| Young Adult | 27 | 2022 | 5717 | 1.000 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2019 | 468 | 0.990 |
Why?
|
| Hypertension | 11 | 2018 | 1535 | 0.970 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2021 | 1085 | 0.970 |
Why?
|
| Acute Kidney Injury | 2 | 2019 | 232 | 0.970 |
Why?
|
| Models, Statistical | 2 | 2019 | 448 | 0.960 |
Why?
|
| Quality Improvement | 6 | 2022 | 413 | 0.960 |
Why?
|
| Forecasting | 3 | 2020 | 277 | 0.950 |
Why?
|
| Length of Stay | 14 | 2021 | 780 | 0.950 |
Why?
|
| Antilymphocyte Serum | 11 | 2017 | 52 | 0.940 |
Why?
|
| Incidence | 12 | 2022 | 1603 | 0.940 |
Why?
|
| Diabetes Complications | 4 | 2018 | 249 | 0.940 |
Why?
|
| Medicare | 6 | 2021 | 319 | 0.900 |
Why?
|
| Anti-Infective Agents | 3 | 2014 | 166 | 0.880 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2023 | 22 | 0.870 |
Why?
|
| United States Department of Veterans Affairs | 8 | 2020 | 307 | 0.860 |
Why?
|
| Liver Neoplasms | 4 | 2016 | 334 | 0.850 |
Why?
|
| Proportional Hazards Models | 12 | 2018 | 792 | 0.840 |
Why?
|
| Histocompatibility Testing | 2 | 2020 | 38 | 0.830 |
Why?
|
| Cardiovascular Diseases | 5 | 2020 | 940 | 0.820 |
Why?
|
| Everolimus | 2 | 2019 | 26 | 0.800 |
Why?
|
| Adolescent | 25 | 2022 | 8912 | 0.800 |
Why?
|
| Delivery of Health Care | 4 | 2020 | 445 | 0.790 |
Why?
|
| Calcineurin Inhibitors | 2 | 2018 | 24 | 0.780 |
Why?
|
| Multivariate Analysis | 11 | 2017 | 1046 | 0.760 |
Why?
|
| Pharmacology, Clinical | 1 | 2021 | 13 | 0.760 |
Why?
|
| No-Show Patients | 2 | 2021 | 9 | 0.760 |
Why?
|
| Sirolimus | 5 | 2016 | 118 | 0.750 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2021 | 212 | 0.740 |
Why?
|
| Aged, 80 and over | 18 | 2021 | 4848 | 0.720 |
Why?
|
| Antiviral Agents | 6 | 2017 | 211 | 0.700 |
Why?
|
| Donor Selection | 1 | 2020 | 29 | 0.690 |
Why?
|
| Hospital Costs | 3 | 2017 | 117 | 0.690 |
Why?
|
| Smartphone | 2 | 2019 | 69 | 0.680 |
Why?
|
| Ganciclovir | 5 | 2017 | 27 | 0.650 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2022 | 504 | 0.640 |
Why?
|
| End Stage Liver Disease | 4 | 2021 | 60 | 0.630 |
Why?
|
| South Carolina | 15 | 2021 | 2752 | 0.630 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 240 | 0.620 |
Why?
|
| Immunoglobulin G | 5 | 2017 | 481 | 0.610 |
Why?
|
| Pharmaceutical Services | 2 | 2015 | 47 | 0.610 |
Why?
|
| Survival Rate | 11 | 2019 | 1056 | 0.600 |
Why?
|
| Algorithms | 5 | 2020 | 1196 | 0.600 |
Why?
|
| Certification | 1 | 2018 | 66 | 0.600 |
Why?
|
| Waiting Lists | 6 | 2021 | 104 | 0.590 |
Why?
|
| Drug Administration Schedule | 8 | 2020 | 567 | 0.580 |
Why?
|
| Creatinine | 6 | 2016 | 243 | 0.580 |
Why?
|
| Cross-Sectional Studies | 12 | 2022 | 2279 | 0.570 |
Why?
|
| Kidney Function Tests | 7 | 2019 | 114 | 0.570 |
Why?
|
| Health Care Rationing | 1 | 2017 | 32 | 0.560 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 581 | 0.560 |
Why?
|
| Medication Reconciliation | 4 | 2021 | 18 | 0.560 |
Why?
|
| Hypoglycemic Agents | 2 | 2019 | 362 | 0.560 |
Why?
|
| Quality Indicators, Health Care | 2 | 2017 | 136 | 0.560 |
Why?
|
| Analgesics, Opioid | 6 | 2022 | 498 | 0.550 |
Why?
|
| Odds Ratio | 6 | 2021 | 880 | 0.550 |
Why?
|
| Antibodies, Monoclonal | 4 | 2017 | 511 | 0.550 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2017 | 376 | 0.550 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2019 | 202 | 0.540 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 42 | 0.540 |
Why?
|
| Steroids | 1 | 2016 | 84 | 0.540 |
Why?
|
| Risk Assessment | 10 | 2021 | 2007 | 0.530 |
Why?
|
| Hospitalization | 6 | 2021 | 978 | 0.530 |
Why?
|
| Transplantation | 2 | 2012 | 23 | 0.530 |
Why?
|
| Electronic Health Records | 5 | 2020 | 374 | 0.530 |
Why?
|
| Social Class | 1 | 2016 | 127 | 0.530 |
Why?
|
| Perioperative Care | 2 | 2015 | 100 | 0.520 |
Why?
|
| Registries | 5 | 2018 | 733 | 0.520 |
Why?
|
| Antihypertensive Agents | 4 | 2015 | 498 | 0.520 |
Why?
|
| Pharmaceutical Preparations | 2 | 2013 | 101 | 0.520 |
Why?
|
| Dyslipidemias | 4 | 2020 | 98 | 0.510 |
Why?
|
| Receptors, Interleukin-2 | 4 | 2016 | 42 | 0.510 |
Why?
|
| Plasma Substitutes | 1 | 2015 | 15 | 0.500 |
Why?
|
| Hydroxyethyl Starch Derivatives | 1 | 2015 | 24 | 0.500 |
Why?
|
| Hepatectomy | 1 | 2015 | 58 | 0.500 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 172 | 0.500 |
Why?
|
| Anti-Bacterial Agents | 2 | 2018 | 1026 | 0.490 |
Why?
|
| Albumins | 1 | 2015 | 72 | 0.490 |
Why?
|
| Kidney Tubules | 1 | 2015 | 80 | 0.490 |
Why?
|
| Fluid Therapy | 1 | 2015 | 59 | 0.480 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2017 | 151 | 0.480 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 163 | 0.470 |
Why?
|
| Lithium Carbonate | 1 | 2014 | 31 | 0.470 |
Why?
|
| Antimanic Agents | 1 | 2014 | 21 | 0.470 |
Why?
|
| Comorbidity | 6 | 2019 | 1426 | 0.460 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 446 | 0.460 |
Why?
|
| Thiazides | 1 | 2013 | 6 | 0.460 |
Why?
|
| Parenteral Nutrition | 1 | 2013 | 39 | 0.450 |
Why?
|
| Diabetes Mellitus | 7 | 2018 | 694 | 0.440 |
Why?
|
| Benchmarking | 1 | 2013 | 91 | 0.440 |
Why?
|
| Diuretics | 1 | 2013 | 97 | 0.440 |
Why?
|
| Disease Management | 2 | 2019 | 248 | 0.440 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 191 | 0.430 |
Why?
|
| Databases, Factual | 4 | 2017 | 622 | 0.430 |
Why?
|
| Opioid-Related Disorders | 3 | 2022 | 298 | 0.420 |
Why?
|
| Renal Dialysis | 3 | 2023 | 174 | 0.420 |
Why?
|
| Prognosis | 10 | 2020 | 2093 | 0.420 |
Why?
|
| Logistic Models | 5 | 2017 | 1420 | 0.410 |
Why?
|
| Opportunistic Infections | 3 | 2018 | 33 | 0.410 |
Why?
|
| Patient Satisfaction | 2 | 2020 | 378 | 0.410 |
Why?
|
| Health Care Costs | 6 | 2020 | 346 | 0.410 |
Why?
|
| Patient Care Management | 1 | 2012 | 40 | 0.410 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2020 | 1745 | 0.400 |
Why?
|
| Diabetic Nephropathies | 1 | 2013 | 161 | 0.380 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 3 | 2009 | 32 | 0.370 |
Why?
|
| Biomarkers | 7 | 2021 | 1593 | 0.360 |
Why?
|
| Patient Safety | 1 | 2012 | 202 | 0.360 |
Why?
|
| Blood Pressure | 5 | 2017 | 1451 | 0.350 |
Why?
|
| Depression | 1 | 2016 | 943 | 0.330 |
Why?
|
| Predictive Value of Tests | 6 | 2021 | 1465 | 0.320 |
Why?
|
| Linear Models | 3 | 2015 | 521 | 0.320 |
Why?
|
| Nephrectomy | 1 | 2009 | 103 | 0.320 |
Why?
|
| Cyclosporine | 2 | 2005 | 121 | 0.310 |
Why?
|
| Intensive Care Units | 4 | 2021 | 344 | 0.310 |
Why?
|
| Residence Characteristics | 2 | 2020 | 252 | 0.310 |
Why?
|
| Frail Elderly | 2 | 2018 | 31 | 0.310 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2018 | 26 | 0.310 |
Why?
|
| Tissue Donors | 4 | 2022 | 195 | 0.300 |
Why?
|
| Frailty | 2 | 2018 | 34 | 0.300 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2017 | 536 | 0.300 |
Why?
|
| Heart-Assist Devices | 2 | 2021 | 221 | 0.300 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2007 | 95 | 0.300 |
Why?
|
| Mortality | 2 | 2018 | 163 | 0.290 |
Why?
|
| ROC Curve | 4 | 2016 | 392 | 0.280 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2019 | 161 | 0.280 |
Why?
|
| Withholding Treatment | 2 | 2016 | 35 | 0.270 |
Why?
|
| Referral and Consultation | 3 | 2020 | 383 | 0.270 |
Why?
|
| Osteoporosis | 1 | 2007 | 88 | 0.270 |
Why?
|
| Quality of Life | 3 | 2022 | 1515 | 0.270 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2019 | 155 | 0.270 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2005 | 35 | 0.260 |
Why?
|
| BK Virus | 3 | 2018 | 17 | 0.260 |
Why?
|
| Polyomavirus Infections | 3 | 2018 | 17 | 0.260 |
Why?
|
| Thrombosis | 4 | 2014 | 218 | 0.260 |
Why?
|
| Biopsy | 5 | 2021 | 540 | 0.260 |
Why?
|
| Survival Analysis | 3 | 2019 | 714 | 0.250 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2019 | 529 | 0.240 |
Why?
|
| Drug Therapy, Combination | 6 | 2018 | 649 | 0.240 |
Why?
|
| Chi-Square Distribution | 5 | 2017 | 546 | 0.230 |
Why?
|
| Child | 10 | 2022 | 6405 | 0.230 |
Why?
|
| Body Mass Index | 3 | 2017 | 867 | 0.230 |
Why?
|
| Reproducibility of Results | 6 | 2021 | 2077 | 0.230 |
Why?
|
| Medication Therapy Management | 3 | 2018 | 32 | 0.230 |
Why?
|
| Child, Preschool | 6 | 2021 | 3187 | 0.230 |
Why?
|
| Fibrinolytic Agents | 3 | 2014 | 377 | 0.220 |
Why?
|
| Blood Glucose | 3 | 2018 | 631 | 0.220 |
Why?
|
| Vancomycin | 1 | 2003 | 60 | 0.210 |
Why?
|
| Pilot Projects | 4 | 2020 | 1342 | 0.210 |
Why?
|
| Cholesterol, LDL | 2 | 2020 | 161 | 0.210 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2015 | 186 | 0.200 |
Why?
|
| Age Factors | 3 | 2016 | 1864 | 0.200 |
Why?
|
| Transplantation, Homologous | 3 | 2019 | 242 | 0.200 |
Why?
|
| Patient Care Team | 3 | 2015 | 311 | 0.200 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2021 | 41 | 0.200 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 11 | 0.200 |
Why?
|
| Pharmacy | 1 | 2021 | 26 | 0.190 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 1851 | 0.190 |
Why?
|
| Liver Cirrhosis | 2 | 2015 | 301 | 0.190 |
Why?
|
| Music Therapy | 1 | 2020 | 2 | 0.190 |
Why?
|
| Regional Medical Programs | 1 | 2020 | 22 | 0.190 |
Why?
|
| Appointments and Schedules | 2 | 2021 | 47 | 0.190 |
Why?
|
| Anesthesiologists | 1 | 2021 | 30 | 0.190 |
Why?
|
| Smoking | 1 | 2009 | 1452 | 0.180 |
Why?
|
| Cost Savings | 1 | 2021 | 110 | 0.180 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2020 | 31 | 0.180 |
Why?
|
| Academic Medical Centers | 2 | 2012 | 281 | 0.180 |
Why?
|
| Genotype | 1 | 2023 | 786 | 0.180 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 27 | 0.180 |
Why?
|
| Single-Blind Method | 1 | 2021 | 249 | 0.180 |
Why?
|
| Kidney | 4 | 2022 | 945 | 0.180 |
Why?
|
| Hospital Administration | 1 | 2020 | 43 | 0.180 |
Why?
|
| Chloramphenicol | 1 | 2000 | 7 | 0.180 |
Why?
|
| Conscious Sedation | 1 | 2020 | 61 | 0.180 |
Why?
|
| Heparin | 3 | 2021 | 205 | 0.180 |
Why?
|
| Socioeconomic Factors | 3 | 2021 | 955 | 0.180 |
Why?
|
| Thrombocytopenia | 3 | 2012 | 122 | 0.180 |
Why?
|
| Reminder Systems | 1 | 2020 | 39 | 0.180 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 349 | 0.180 |
Why?
|
| Veterans Health | 1 | 2020 | 62 | 0.180 |
Why?
|
| Transcriptome | 1 | 2021 | 164 | 0.180 |
Why?
|
| Delayed-Action Preparations | 1 | 2020 | 120 | 0.180 |
Why?
|
| Tonsillectomy | 1 | 2021 | 69 | 0.170 |
Why?
|
| Paraspinal Muscles | 1 | 2019 | 5 | 0.170 |
Why?
|
| Nursing Care | 1 | 2019 | 18 | 0.170 |
Why?
|
| Interdisciplinary Communication | 2 | 2017 | 93 | 0.170 |
Why?
|
| Cost of Illness | 1 | 2021 | 206 | 0.170 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 37 | 0.170 |
Why?
|
| Prescription Drug Monitoring Programs | 1 | 2020 | 34 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 96 | 0.170 |
Why?
|
| Cytomegalovirus | 3 | 2017 | 63 | 0.170 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 498 | 0.170 |
Why?
|
| Arteriovenous Malformations | 1 | 2019 | 34 | 0.160 |
Why?
|
| Antibodies, Viral | 2 | 2013 | 110 | 0.160 |
Why?
|
| DNA | 1 | 2021 | 597 | 0.160 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 1753 | 0.160 |
Why?
|
| Abatacept | 1 | 2018 | 17 | 0.160 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 163 | 0.160 |
Why?
|
| Internet | 2 | 2019 | 390 | 0.160 |
Why?
|
| Multimorbidity | 1 | 2018 | 7 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 767 | 0.160 |
Why?
|
| Geographic Mapping | 1 | 2018 | 19 | 0.160 |
Why?
|
| User-Computer Interface | 1 | 2020 | 230 | 0.160 |
Why?
|
| Muscle Weakness | 1 | 2018 | 26 | 0.160 |
Why?
|
| Educational Status | 2 | 2016 | 273 | 0.160 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 2800 | 0.150 |
Why?
|
| Adipose Tissue | 1 | 2019 | 221 | 0.150 |
Why?
|
| Resource Allocation | 1 | 2018 | 35 | 0.150 |
Why?
|
| Program Development | 1 | 2019 | 240 | 0.150 |
Why?
|
| Infant | 4 | 2021 | 2891 | 0.150 |
Why?
|
| Area Under Curve | 2 | 2016 | 238 | 0.150 |
Why?
|
| Muromonab-CD3 | 1 | 2017 | 8 | 0.150 |
Why?
|
| Alemtuzumab | 1 | 2017 | 10 | 0.150 |
Why?
|
| Health Resources | 1 | 2018 | 76 | 0.150 |
Why?
|
| Bias | 1 | 2018 | 148 | 0.150 |
Why?
|
| Blood Cell Count | 1 | 2017 | 35 | 0.150 |
Why?
|
| Electrolytes | 1 | 2017 | 47 | 0.150 |
Why?
|
| Propensity Score | 2 | 2015 | 117 | 0.150 |
Why?
|
| Anxiety | 1 | 2020 | 422 | 0.150 |
Why?
|
| Immunoglobulins | 1 | 2017 | 97 | 0.150 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 62 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2012 | 300 | 0.150 |
Why?
|
| Preoperative Period | 2 | 2018 | 50 | 0.150 |
Why?
|
| Rabbits | 2 | 2015 | 509 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 468 | 0.140 |
Why?
|
| Acyclovir | 2 | 2014 | 38 | 0.140 |
Why?
|
| Health Facilities | 1 | 2017 | 36 | 0.140 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 185 | 0.140 |
Why?
|
| Liver Function Tests | 1 | 2017 | 114 | 0.140 |
Why?
|
| Tumor Virus Infections | 2 | 2018 | 32 | 0.140 |
Why?
|
| Medical Assistance | 1 | 2016 | 9 | 0.140 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 67 | 0.140 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 36 | 0.140 |
Why?
|
| Liver Failure | 2 | 2013 | 27 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 931 | 0.140 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 711 | 0.140 |
Why?
|
| Financing, Personal | 1 | 2016 | 17 | 0.140 |
Why?
|
| Histocompatibility | 1 | 2016 | 17 | 0.140 |
Why?
|
| Isoantibodies | 1 | 2016 | 35 | 0.140 |
Why?
|
| Apgar Score | 1 | 2016 | 22 | 0.140 |
Why?
|
| Workflow | 1 | 2017 | 100 | 0.140 |
Why?
|
| HLA Antigens | 1 | 2016 | 82 | 0.130 |
Why?
|
| Age Distribution | 1 | 2016 | 320 | 0.130 |
Why?
|
| Epitopes | 1 | 2016 | 146 | 0.130 |
Why?
|
| Community Health Services | 1 | 2017 | 141 | 0.130 |
Why?
|
| Lipids | 1 | 2017 | 298 | 0.130 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2015 | 69 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 2 | 2014 | 504 | 0.130 |
Why?
|
| Atrophy | 1 | 2015 | 112 | 0.130 |
Why?
|
| Medical Records | 1 | 2015 | 121 | 0.130 |
Why?
|
| Cholesterol | 1 | 2016 | 331 | 0.130 |
Why?
|
| Employment | 1 | 2016 | 154 | 0.120 |
Why?
|
| Antidepressive Agents | 1 | 2016 | 216 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2016 | 1553 | 0.120 |
Why?
|
| Cholelithiasis | 1 | 2015 | 66 | 0.120 |
Why?
|
| Risk | 2 | 2013 | 563 | 0.120 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2015 | 59 | 0.120 |
Why?
|
| Biliary Tract Diseases | 1 | 2014 | 50 | 0.120 |
Why?
|
| Health Care Surveys | 1 | 2015 | 239 | 0.120 |
Why?
|
| Prednisone | 1 | 2014 | 104 | 0.120 |
Why?
|
| Sex Factors | 2 | 2020 | 1266 | 0.120 |
Why?
|
| Superior Sagittal Sinus | 1 | 2013 | 8 | 0.120 |
Why?
|
| Drug Interactions | 3 | 2005 | 289 | 0.110 |
Why?
|
| Urban Population | 1 | 2015 | 255 | 0.110 |
Why?
|
| Self Administration | 1 | 2015 | 419 | 0.110 |
Why?
|
| Micronutrients | 1 | 2013 | 31 | 0.110 |
Why?
|
| Hyperkalemia | 1 | 2013 | 21 | 0.110 |
Why?
|
| Models, Organizational | 1 | 2014 | 97 | 0.110 |
Why?
|
| Coagulants | 1 | 2013 | 4 | 0.110 |
Why?
|
| Fibrosis | 1 | 2015 | 371 | 0.110 |
Why?
|
| Antineoplastic Agents | 3 | 2012 | 1070 | 0.110 |
Why?
|
| Factor VIIa | 1 | 2013 | 25 | 0.110 |
Why?
|
| Potassium | 1 | 2013 | 168 | 0.110 |
Why?
|
| Decision Making | 1 | 2016 | 410 | 0.110 |
Why?
|
| Fatty Liver | 1 | 2013 | 97 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2014 | 114 | 0.110 |
Why?
|
| Hepatic Artery | 1 | 2012 | 25 | 0.110 |
Why?
|
| Antithrombins | 1 | 2012 | 32 | 0.110 |
Why?
|
| Cell Phone | 1 | 2013 | 44 | 0.100 |
Why?
|
| Blood Loss, Surgical | 1 | 2013 | 79 | 0.100 |
Why?
|
| Lung Neoplasms | 3 | 2012 | 1173 | 0.100 |
Why?
|
| Postoperative Period | 2 | 2016 | 238 | 0.100 |
Why?
|
| Drugs, Generic | 1 | 2012 | 17 | 0.100 |
Why?
|
| Depressive Disorder | 1 | 2016 | 621 | 0.100 |
Why?
|
| Monitoring, Ambulatory | 1 | 2013 | 84 | 0.100 |
Why?
|
| Isoxazoles | 1 | 2012 | 22 | 0.100 |
Why?
|
| Kidney Diseases | 2 | 2018 | 307 | 0.100 |
Why?
|
| Aspirin | 1 | 2012 | 295 | 0.090 |
Why?
|
| Heart Failure | 1 | 2020 | 1180 | 0.090 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 188 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 2223 | 0.090 |
Why?
|
| Hospital Mortality | 3 | 2018 | 384 | 0.090 |
Why?
|
| Prevalence | 1 | 2014 | 1619 | 0.090 |
Why?
|
| Protein C | 1 | 2009 | 4 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 425 | 0.080 |
Why?
|
| Pain, Postoperative | 2 | 2022 | 214 | 0.080 |
Why?
|
| Hospitals | 2 | 2022 | 265 | 0.080 |
Why?
|
| Thrombin | 1 | 2009 | 117 | 0.080 |
Why?
|
| Inflammation | 1 | 2014 | 1030 | 0.080 |
Why?
|
| Kidney Neoplasms | 2 | 2000 | 206 | 0.070 |
Why?
|
| Renin-Angiotensin System | 1 | 2007 | 79 | 0.070 |
Why?
|
| Proteinuria | 1 | 2007 | 136 | 0.070 |
Why?
|
| Diphosphonates | 1 | 2007 | 39 | 0.070 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2007 | 140 | 0.070 |
Why?
|
| Colorectal Neoplasms | 2 | 2005 | 561 | 0.070 |
Why?
|
| Health Status | 1 | 2009 | 429 | 0.070 |
Why?
|
| Sepsis | 1 | 2009 | 233 | 0.070 |
Why?
|
| Therapeutic Equivalency | 1 | 2005 | 21 | 0.070 |
Why?
|
| Recombinant Proteins | 3 | 2013 | 742 | 0.060 |
Why?
|
| Cadaver | 2 | 2004 | 136 | 0.060 |
Why?
|
| Camptothecin | 1 | 2005 | 39 | 0.060 |
Why?
|
| Patient Discharge | 2 | 2021 | 294 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2005 | 88 | 0.060 |
Why?
|
| Leukopenia | 1 | 2004 | 23 | 0.060 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2004 | 15 | 0.060 |
Why?
|
| Postoperative Care | 2 | 2016 | 163 | 0.060 |
Why?
|
| Pancreas | 2 | 2021 | 225 | 0.060 |
Why?
|
| Obesity | 2 | 2018 | 1076 | 0.060 |
Why?
|
| Income | 2 | 2016 | 167 | 0.060 |
Why?
|
| Metabolic Clearance Rate | 1 | 2003 | 48 | 0.050 |
Why?
|
| Drug Evaluation | 1 | 2003 | 47 | 0.050 |
Why?
|
| Animals | 3 | 2015 | 20881 | 0.050 |
Why?
|
| Cooperative Behavior | 2 | 2015 | 235 | 0.050 |
Why?
|
| Recurrence | 2 | 2015 | 948 | 0.050 |
Why?
|
| Rosaniline Dyes | 1 | 2001 | 2 | 0.050 |
Why?
|
| Osmolar Concentration | 1 | 2002 | 134 | 0.050 |
Why?
|
| Appendectomy | 1 | 2022 | 47 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 58 | 0.050 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 43 | 0.050 |
Why?
|
| Ventilators, Mechanical | 1 | 2021 | 13 | 0.050 |
Why?
|
| Pain, Procedural | 1 | 2020 | 4 | 0.050 |
Why?
|
| Stakeholder Participation | 1 | 2020 | 17 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2003 | 737 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 1 | 2021 | 72 | 0.050 |
Why?
|
| Urticaria | 1 | 2001 | 84 | 0.050 |
Why?
|
| Developing Countries | 1 | 2021 | 106 | 0.050 |
Why?
|
| Self Efficacy | 1 | 2021 | 199 | 0.050 |
Why?
|
| Urban Health | 1 | 2020 | 49 | 0.050 |
Why?
|
| Rural Health | 1 | 2020 | 66 | 0.040 |
Why?
|
| Quinazolines | 2 | 2012 | 70 | 0.040 |
Why?
|
| Hypnotics and Sedatives | 1 | 2020 | 96 | 0.040 |
Why?
|
| Insurance Carriers | 1 | 2020 | 9 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 114 | 0.040 |
Why?
|
| Hospitals, Veterans | 1 | 2020 | 147 | 0.040 |
Why?
|
| Urinary Tract Infections | 1 | 2000 | 71 | 0.040 |
Why?
|
| Sulfonamides | 2 | 2012 | 141 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 193 | 0.040 |
Why?
|
| Flavonoids | 1 | 2000 | 109 | 0.040 |
Why?
|
| Piperidines | 1 | 2000 | 123 | 0.040 |
Why?
|
| Biological Availability | 1 | 2019 | 79 | 0.040 |
Why?
|
| Receptors, Angiotensin | 1 | 2019 | 59 | 0.040 |
Why?
|
| C-Peptide | 1 | 2018 | 23 | 0.040 |
Why?
|
| Hemorrhage | 2 | 2012 | 328 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2021 | 356 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2019 | 49 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2000 | 110 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 55 | 0.040 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 77 | 0.040 |
Why?
|
| Ethnology | 1 | 2018 | 5 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2018 | 82 | 0.040 |
Why?
|
| Geography | 1 | 2018 | 80 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2018 | 31 | 0.040 |
Why?
|
| Inappropriate Prescribing | 1 | 2018 | 27 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2017 | 24 | 0.040 |
Why?
|
| Pyrazines | 1 | 1998 | 46 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2019 | 205 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2017 | 52 | 0.040 |
Why?
|
| Phenotype | 1 | 2020 | 947 | 0.040 |
Why?
|
| Pancreatitis | 1 | 2018 | 279 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 63 | 0.030 |
Why?
|
| Triglycerides | 1 | 2015 | 184 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 951 | 0.030 |
Why?
|
| Conversion to Open Surgery | 1 | 2015 | 6 | 0.030 |
Why?
|
| Contraindications | 1 | 2015 | 52 | 0.030 |
Why?
|
| Direct Service Costs | 1 | 2014 | 8 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2021 | 2455 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 706 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2014 | 17 | 0.030 |
Why?
|
| Health Services Research | 1 | 2015 | 209 | 0.030 |
Why?
|
| Glycemic Index | 1 | 2014 | 28 | 0.030 |
Why?
|
| Government Regulation | 1 | 2014 | 46 | 0.030 |
Why?
|
| Drug Costs | 1 | 2014 | 87 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 652 | 0.030 |
Why?
|
| Hypoglycemia | 1 | 2014 | 72 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2014 | 144 | 0.030 |
Why?
|
| Postoperative Hemorrhage | 1 | 2014 | 69 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 180 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2014 | 90 | 0.030 |
Why?
|
| Pipecolic Acids | 1 | 2012 | 9 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2012 | 12 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2014 | 330 | 0.030 |
Why?
|
| Hirudins | 1 | 2012 | 32 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 1 | 2012 | 57 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2014 | 158 | 0.030 |
Why?
|
| Liver | 1 | 2018 | 1118 | 0.030 |
Why?
|
| Hemostasis | 1 | 2012 | 32 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2012 | 34 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2013 | 91 | 0.030 |
Why?
|
| Crotonates | 1 | 2012 | 3 | 0.030 |
Why?
|
| Hydroxybutyrates | 1 | 2012 | 4 | 0.030 |
Why?
|
| Toluidines | 1 | 2012 | 5 | 0.030 |
Why?
|
| Reoperation | 1 | 2014 | 467 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2013 | 94 | 0.030 |
Why?
|
| Arginine | 1 | 2012 | 102 | 0.030 |
Why?
|
| Biotransformation | 1 | 2012 | 69 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2012 | 52 | 0.030 |
Why?
|
| Nitriles | 1 | 2012 | 68 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 287 | 0.020 |
Why?
|
| Viral Load | 1 | 2012 | 127 | 0.020 |
Why?
|
| Body Weight | 1 | 2013 | 554 | 0.020 |
Why?
|
| Inpatients | 1 | 2012 | 208 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2013 | 275 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 492 | 0.020 |
Why?
|
| Reperfusion Injury | 1 | 2013 | 320 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 2010 | 34 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 483 | 0.020 |
Why?
|
| Health Surveys | 1 | 2012 | 489 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 373 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2013 | 402 | 0.020 |
Why?
|
| Half-Life | 1 | 2009 | 96 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2013 | 403 | 0.020 |
Why?
|
| APACHE | 1 | 2009 | 41 | 0.020 |
Why?
|
| Celecoxib | 1 | 2008 | 22 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2008 | 190 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 800 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 772 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 475 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 629 | 0.010 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2001 | 53 | 0.010 |
Why?
|
| Asthenia | 1 | 2000 | 2 | 0.010 |
Why?
|
| Diarrhea | 1 | 2000 | 63 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2000 | 100 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2000 | 274 | 0.010 |
Why?
|
| Cell Count | 1 | 1998 | 248 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1998 | 369 | 0.010 |
Why?
|